Strasbourg, December 12, 2016 – Defymed announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the MailPan® bio-artificial pancreas, in combination with stem-cell derived differentiated insulin-secreting cells developed by Semma Therapeutics. The combination will be evaluated for effectiveness and safety, at first in vitro and then in an animal model. For more info